Sanofi likely bolstered the chances of its multiple sclerosis candidate tolebrutinib finding a treatment niche on 20 September as it reported data from the Phase III HERCULES study showing that the BTK inhibitor can delay disability progression in non-relapsing secondary progressive MS (nrSPMS) while demonstrating what one analyst called a manageable liver safety profile.
Key Takeaways
-
Sanofi’s BTK inhibitor tolebrutinib may offer a delay in confirmed disability in a subset of MS patients, new data from a Phase III study shows.
...
The data, presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Copenhagen, came roughly three weeks after Sanofi announced that tolebrutinib missed its primary...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?